Julie R Park

21PUBLICATIONS
173CO-AUTHORS
Molecular targetsInfant and child healthPredictive and prognostic markersHaematological tumoursSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jun 18, 2026
The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma.

|Dec 23, 2025
Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project.

Wendy B London, Gabriela Villanueva, Derek Shyr

|Oct 27, 2025
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group.

Florette K Hazard, Angus M S Toland, Serena Y Tan

|Sep 17, 2025
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity.

Shivendra Singh, Jie Fang, Hongjian Jin

|Aug 12, 2025
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors.

Kenneth B DeSantes, Kimberly A McDowell, Paul M Sondel

|Jun 23, 2025
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Thomas Cash, Araz Marachelian, Steven G DuBois

Pageof 4

Frequent Collaborators

8 joint publications

Wenjun Huang

8 joint publications

Navin Pinto

7 joint publications

Rebecca Gardner

6 joint publications

Arlene Naranjo